Pasithea Therapeutics Corp.
$0.72
▲
3.48%
2026-04-21 07:47:00
www.pasithea.com
NCM: KTTA
Explore Pasithea Therapeutics Corp. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$18.52 M
Current Price
$0.72
52W High / Low
$3.79 / $0.28
Stock P/E
—
Book Value
$2.39
Dividend Yield
—
ROCE
-37.74%
ROE
-58.36%
Face Value
—
EPS
$-2.91
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
5
Beta
0.25
Debt / Equity
—
Current Ratio
11.35
Quick Ratio
11.35
Forward P/E
-0.33
Price / Sales
—
Enterprise Value
$-37.7 M
EV / EBITDA
2.35
EV / Revenue
—
Rating
Strong Buy
Target Price
$3
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Cytokinetics, Incorporated | $65.05 | — | $8.11 B | — | -50.1% | 197.47% | $70.98 / $29.31 | $-5.37 |
| 2. | Reviva Pharmaceuticals Holdings, Inc. | $0.91 | — | $10.89 M | — | -233.59% | -4.2% | $23.2 / $0.59 | $1.47 |
| 3. | Maze Therapeutics, Inc. | $26.84 | — | $1.4 B | — | -38.15% | -47.52% | $53.65 / $7.16 | $7.2 |
| 4. | XORTX Therapeutics Inc. | $2.25 | — | $4.16 M | — | -156.2% | -98% | $9.85 / $2.42 | $0.3 |
| 5. | Rapport Therapeutics, Inc. | $37.14 | — | $1.9 B | — | -25.36% | -28.22% | $42.27 / $7.73 | $10.14 |
| 6. | Phio Pharmaceuticals Corp. | $1.27 | — | $14.75 M | — | -45.76% | -69.95% | $4.19 / $0.81 | $1.73 |
| 7. | Eikon Therapeutics, Inc. | $11.55 | — | $644.25 M | — | -62.8% | -1.25% | $17.4 / $8.58 | $-286.47 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -10.26 M | -3.11 M | -3.81 M | -3.68 M | -3.26 M | — |
| Net Profit | -10.11 M | -3.04 M | -3.72 M | -3.56 M | -3.18 M | — |
| EPS in Rs | -0.41 | -0.12 | -0.15 | -0.14 | -0.13 | -2.87 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -20.86 M | -14.25 M | -15.98 M | -12.59 M |
| Net Profit | -20.43 M | -13.9 M | -15.96 M | -13.94 M |
| EPS in Rs | -0.82 | -0.56 | -0.64 | -0.56 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 60.24 M | 16.06 M | 26.12 M | 45.18 M |
| Total Liabilities | 5.02 M | 1.28 M | 2.72 M | 2.68 M |
| Equity | 55.22 M | 14.78 M | 23.4 M | 42.5 M |
| Current Assets | 56.46 M | 7.37 M | 16.69 M | 34.08 M |
| Current Liabilities | 4.97 M | 1.12 M | 2.63 M | 1.88 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -15.21 M | -13.92 M | -13.43 M | -13.69 M |
| Investing CF | 0.01 M | 0 M | 0.4 M | -2.93 M |
| Financing CF | 63.52 M | 4.52 M | -3.73 M | -3.21 M |
| Free CF | -15.21 M | -13.92 M | -13.46 M | -13.8 M |
| Capex | — | — | -0.03 M | -0.11 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 12.89% | -14.53% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-01-02 | 1:0.05 |